Research and Markets (http://www.researchandmarkets.com/research/g4w2k7/global)
has announced the addition of the "Global
Hypercholesterolemia Market 2014-2018" report to their offering.
The Global Hypercholesterolemia market will grow at a CAGR of 3.81% to
This report covers the present scenario and the growth prospects of the
Global Hypercholesterolemia market for the period 2014-2018. To
calculate the market size, the report considers revenue generated
through the sales of various hypercholesterolemia management drugs that
are available in the market which includes statins and other serum lipid
lowering drugs. The report also presents the vendor landscape and a
corresponding detailed analysis of the top five vendors in the Global
Hypercholesterolemia market. In addition, it discusses the major drivers
that influence the growth of the market. It also outlines the challenges
faced by the vendors and the market at large, as well as the key trends
that are emerging in the market.
The Hypercholesteroemia market is associated with fierce competition
among the market vendors for innovator drugs and generic manufacturers.
The existing competition is expected to rise in the forecast period
owing to the launch of generic versions for drugs that are set to lose
their patent protection in the near-term. For instance, the 2013 fourth
quarter sales for Crestor declined in Canada and Australia owing to the
loss of exclusivity in these territories. Further, the drug is expected
to face an additional decrease in sales as the US patent for the drug
candidate is set to expire in 2016, while in the EU and Japan the patent
will expire in 2017. In November 2011, Lipitor lost its exclusivity in
the US market. Following the entry of its generic versions in May 2012,
the US sales of Lipitor decreased by 81 percent in 2012 as compared to
the 2011 US sales.
According to the report, one of the main drivers in the market is the
increasing risk of cardiovascular diseases. Hypercholesterolemia is one
of the underlying causes for CVDs. WHO reported that in men aged 40
years, a 10 percent decrease in serum cholesterol levels is associated
with a 50 percent reduction in heart disease within 5 years. Hence, risk
management for CVDs also involves the reduction of hypercholesterolemia.
Key Topics Covered:
For more information visit http://www.researchandmarkets.com/research/g4w2k7/global
[ Back To NFVZone's Homepage ]